A randomized-controlled trial of AST-OPC1 in patients with Spinal-cord-injuries
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2018
At a glance
- Drugs OPC 1 (Primary)
- Indications Spinal cord injuries
- Focus Therapeutic Use
- 31 Jul 2018 According to an Asterias Biotherapeutics media release, the company expects to submit an application to the California Institute of Regenerative Medicine (CIRM) to apply for funding to support this study.
- 09 Feb 2017 According to an Asterias Biotherapeutics media release, company expect to commence this trial in early 2018.
- 09 Feb 2017 New trial record